BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dusselier M, Deluche E, Delacourt N, Ballouhey J, Egenod T, Melloni B, Vergnenègre C, Veillon R, Vergnenègre A. Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers. PLoS One 2019;14:e0219060. [PMID: 31314761 DOI: 10.1371/journal.pone.0219060] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhou K, Cao J, Lin H, Liang L, Shen Z, Wang L, Peng Z, Mei J. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis. Front Oncol 2022;12:962173. [DOI: 10.3389/fonc.2022.962173] [Reference Citation Analysis]
2 Guven DC, Sahin TK, Erul E, Cakir IY, Ucgul E, Yildirim HC, Aktepe OH, Erman M, Kilickap S, Aksoy S, Yalcin S. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. JCM 2022;11:4523. [DOI: 10.3390/jcm11154523] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
4 Wang H, Li C, Yang R, Jin J, Liu D, Li W. Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis. PLoS One 2022;17:e0268288. [PMID: 35522679 DOI: 10.1371/journal.pone.0268288] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Petruzzelli M, Ferrer M, Schuijs MJ, Kleeman SO, Mourikis N, Hall Z, Perera D, Raghunathan S, Vacca M, Gaude E, Lukey MJ, Jodrell DI, Frezza C, Wagner EF, Venkitaraman AR, Halim TYF, Janowitz T. Early Neutrophilia Marked by Aerobic Glycolysis Sustains Host Metabolism and Delays Cancer Cachexia. Cancers (Basel) 2022;14. [PMID: 35205709 DOI: 10.3390/cancers14040963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Iijima Y, Ishikawa M, Iwai S, Yamagata A, Motono N, Uramoto H. Is Overweight Related to the Prognosis of Octogenarians with Lung Cancer? OBES SURG. [DOI: 10.1007/s11695-022-05948-7] [Reference Citation Analysis]
7 Liu N, Mao J, Tao P, Chi H, Jia W, Dong C. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. [PMID: 35060536 DOI: 10.1097/MD.0000000000028617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
8 Rice SJ, Belani CP. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer. PLoS One 2021;16:e0260988. [PMID: 34855926 DOI: 10.1371/journal.pone.0260988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. Eur J Cancer 2021;151:211-20. [PMID: 34022698 DOI: 10.1016/j.ejca.2021.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
10 Shi WJ, Zhao W. Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. Chin Med J (Engl) 2020;133:2466-75. [PMID: 32960841 DOI: 10.1097/CM9.0000000000001090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Lim JU, Kang HS, Yeo CD, Kim JS, Park CK, Kim JW, Kim SJ, Lee SH. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. J Thorac Dis 2021;13:2824-32. [PMID: 34164174 DOI: 10.21037/jtd-20-3416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ayers KL, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, Newman S, Zhou X, Hirsch FR, Mack PC, Liu JJ, Schadt EE, Chen R, Li SD. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer 2021;21:441. [PMID: 33882890 DOI: 10.1186/s12885-021-08194-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, Nicolardi L, Caglio A, Aerts S, Cortellini A, Ficorella C, Chiari R, Di Maio M, Dingemans AC, Aerts JGJV, Berardi R. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. J Clin Med 2021;10:1005. [PMID: 33801320 DOI: 10.3390/jcm10051005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
14 Chen S, Li R, Zhang Z, Huang Z, Cui P, Jia W, Zhang S, Tao H, Wang L, Li X, Wang J, Ma J, Liu Z, Huang D, Zheng X, Saito Y, Ichiki Y, Hu Y. Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors. Transl Lung Cancer Res 2021;10:1397-407. [PMID: 33889518 DOI: 10.21037/tlcr-21-43] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Iijima Y, Iwai S, Yamagata A, Motono N, Usuda K, Yamagishi S, Koizumi K, Uramoto H. Is lung resection appropriate for late octogenarians? Surgical outcomes of patients aged ≥ 80 years with lung cancer. Clin Transl Oncol 2021;23:1585-92. [PMID: 33502740 DOI: 10.1007/s12094-021-02554-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Viñal D, Gutierrez-sainz L, Martinez D, Garcia-cuesta JA, Pedregosa J, Villamayor J, Ostios L, Sanchez-cabrero D, Higuera O, Pinto A, Rodriguez-salas N, Espinosa E, de Castro J, Feliu J. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clin Transl Oncol 2021;23:1185-92. [DOI: 10.1007/s12094-020-02509-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
17 Huang Y, Shen A. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis. Medicine (Baltimore) 2020;99:e21718. [PMID: 32846790 DOI: 10.1097/MD.0000000000021718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Rapoport BL, Theron AJ, Vorobiof DA, Langenhoven L, Hall JM, Van Eeden RI, Smit T, Chan SW, Botha MC, Raats JI, Necker M, Anderson R. Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer. Lung Cancer Manag 2020;9:LMT37. [PMID: 32774468 DOI: 10.2217/lmt-2020-0014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Knetki-Wróblewska M, Kowalski DM, Krzakowski M. Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer-Daily Practice versus Clinical Trials. J Clin Med 2020;9:E2273. [PMID: 32708936 DOI: 10.3390/jcm9072273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G, Chen R, Jiao S, Wang J. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol 2020;10:654. [PMID: 32656072 DOI: 10.3389/fonc.2020.00654] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
21 Gascón M, Isla D, Cruellas M, Gálvez EM, Lastra R, Ocáriz M, Paño JR, Ramírez A, Sesma A, Torres-Ramón I, Yubero A, Pardo J, Martínez-Lostao L. Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Cells 2020;9:E1525. [PMID: 32580514 DOI: 10.3390/cells9061525] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Rossi S, Toschi L, Finocchiaro G, Santoro A. Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy 2020;12:715-24. [PMID: 32522052 DOI: 10.2217/imt-2019-0154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Zhang N, Jiang J, Tang S, Sun G. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol 2020;85:106677. [PMID: 32531712 DOI: 10.1016/j.intimp.2020.106677] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 12.7] [Reference Citation Analysis]
24 Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open 2020;10:e035031. [PMID: 32499266 DOI: 10.1136/bmjopen-2019-035031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
25 Dall'Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data. Lung Cancer 2020;145:95-104. [PMID: 32417680 DOI: 10.1016/j.lungcan.2020.04.027] [Cited by in Crossref: 49] [Cited by in F6Publishing: 59] [Article Influence: 16.3] [Reference Citation Analysis]
26 Ozdemir Y, Topkan E, Mertsoylu H, Selek U. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy. Cancer Manag Res 2020;12:1959-67. [PMID: 32214853 DOI: 10.2147/CMAR.S248034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
27 Tamura D, Jinnouchi N, Abe M, Ikarashi D, Matsuura T, Kato R, Maekawa S, Kato Y, Kanehira M, Takata R, Obara W. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice. Int J Clin Oncol 2020;25:899-905. [PMID: 31907720 DOI: 10.1007/s10147-019-01613-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]